Clinical Trials Sponsored by Novo Nordisk A/S

Total 1552 results

Novo Nordisk A/S

Completed

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Russian Federation, Serbia, Turkey, Algeria, Czechia
Novo Nordisk A/S

Completed

A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam (DiabCare Asia)

Diabetes Mellitus, Type 2 | Diabetes

Vietnam
Novo Nordisk A/S

Completed

Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus (ReFLeCT)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Switzerland, Denmark, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Novo Nordisk A/S

Completed

A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects

Healthy Volunteers | Growth Hormone Deficiency

Germany
Novo Nordisk A/S

Completed

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, United Kingdom, Canada, Austria, Serbia, Germany, South Africa, Malaysia, Czechia
Novo Nordisk A/S

Completed

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Italy, Mexico, Russian Federation, United Kingdom, Spain, Malaysia, Croatia, Greece, Korea, Republic of, Japan, South Africa, Algeria, Thailand, Argentina, Brazil, Canada, Romania
Novo Nordisk A/S

Completed

Awareness, Care & Treatment in Obesity Management (ACTION) Study (ACTION)

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Awareness, Care and Treatment in Obesity Management

Obesity | Metabolism and Nutrition Disorder

Canada
Novo Nordisk A/S

Completed

A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine

Diabetes Mellitus, Type 2

Denmark
Novo Nordisk A/S

Completed

Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Italy, Mexico, Poland, Russian Federation, Spain, Canada, Denmark, Taiwan, Malaysia, United Kingdom, Turkey, Germany, Bulgaria, Argentina, Australia, Thailand, Algeria, Brazil
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Italy, Puerto Rico, United Kingdom, Argentina, Finland, Serbia, Germany, France, Greece, Netherlands, Switzerland
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

Germany, France, United States, Japan, Netherlands, Russian Federation, Bulgaria, United Kingdom, North Macedonia, South Africa, Italy, Finland
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes (onset®8)

Diabetes | Diabetes Mellitus, Type 1

United States, India, Israel, Italy, Japan, Russian Federation, Canada, Austria, Taiwan, Serbia, Germany, Bulgaria, Puerto Rico
Novo Nordisk A/S

Completed

Awareness, Care & Treatment In Obesity Management - An International Observation (ACTION-IO)

Obesity

United Arab Emirates, Australia, Israel, Korea, Republic of, Mexico, Saudi Arabia, Spain, Switzerland, United Kingdom
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Novo Nordisk A/S

Completed

Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus (EU-TREAT)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Austria, Denmark, Greece, Germany, Switzerland, Italy
Novo Nordisk A/S

Completed

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Russian Federation, United Kingdom, France, Ukraine
Novo Nordisk A/S

Completed

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Turkey, Egypt, Philippines, United Arab Emirates, Bangladesh, Colombia, Singapore, South Africa
Novo Nordisk A/S

Completed

Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes (Jom Mama)

Diabetes Mellitus, Type 2 | Diabetes

Malaysia
Novo Nordisk A/S

Completed

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A (guardian ™9)

Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United States, Germany, Serbia, Taiwan, Bulgaria
Novo Nordisk A/S

Completed

Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing

Foetal Growth Problem | Small for Gestational Age

Japan
Novo Nordisk A/S

Completed

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Hungary, France, Australia
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Spain, Hungary, Mexico, Slovakia, Greece, Argentina, South Africa, Australia
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes (SUSTAIN™)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Diabetes Mellitus, Type 2 | Diabetes

United Arab Emirates, Malaysia, India, South Africa, Algeria, Lebanon
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Terminated

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma (iINHALE 9)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Asthma

United States, Slovakia, India, Malaysia, Australia, Former Serbia and Montenegro
Novo Nordisk A/S

Completed

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, Canada
Novo Nordisk A/S

Completed

Comparison of 2 NovoFine® Needles on the Reflux of Insulin

Diabetes | Diabetes Mellitus, Type 1 | Delivery Systems

Italy
Novo Nordisk A/S

Completed

A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 (paradigm™ 4)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Russian Federation, Turkey, Japan, South Africa, Romania
Novo Nordisk A/S

Completed

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Slovakia, Spain, France, Hungary, Mexico, Russian Federation, Turkey, Czechia, Greece, Argentina
Novo Nordisk A/S

Completed

A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues

Diabetes Mellitus, Type 2 | Diabetes

Poland

3

Subscribe